SY18 - Future Therapies for Obesity: From Oral GLP-1s to Triple Agonists and New Targets

Symposium Chair(s)

• GJ

  Gwendolyne Jack

  Disclosure information not submitted.
• 

  Christos Mantzoros, MD,DSC

  Harvard University
  Watertown, MA, United States

  Disclosure(s): Ansh Inc., LabCorp Inc.,: Collaborative research (); Boehringer Ingelheim, Nestle, Olympus, Genfit, Lumos, Novo Nordisk, Azurity, Amgen, Corcept, Intercept, 89 Bio, Madrigal, Aligos, Esperion, Biodexa and Regeneron: Consultant (); Merck, Abbott, Amgen, Massachusetts Life Sciences Center, Esperion and Boehringer Ingelheim: Contracted Research (Principal Investigators must provide information, even if received by the institution) ()

Recent advances in obesity pharmacotherapy are transforming metabolic care through increasingly potent and diverse mechanisms of action. This session will explore next-generation injectable incretin-based agents, including dual and triple receptor agonists; oral and nonpeptide anti-obesity medications designed to improve accessibility, adherence, and long-term weight maintenance; and emerging pathways beyond gut hormones that may redefine how obesity and metabolic diseases are treated. Speakers will integrate preclinical and clinical insights to highlight innovation in drug design, efficacy, and durability-offering a forward-looking view of the evolving therapeutic landscape for obesity.

Presentations:

• 4:30 PM - 5:00 PM CT

  Beyond the Gut: Muscle-Sparing Therapies for Obesity
  

  Symposium Speaker: Jaime Almandoz, MD, MBA, DABOM, FTOS – UT Southwestern Medical Center
• 5:00 PM - 5:30 PM CT

  Oral and nonpeptide Anti-obesity Medications: Expanding Access and Adherence
  

  Symposium Speaker: Sean Wharton, MD, PharmD (he/him/his)
• 5:30 PM - 6:00 PM CT

  Next-generation Injectable Incretin-based Therapies: Dual and Triple Agonists
  

  Symposium Speaker: David D'Alessio, MD – Duke University School of Medicine